Sareko albisteak
Itzuli orri hau
2020-12-04
SOUTH PLAINFIELD, N.J., Dec. 4, 2020 -- (Healthcare Sales & Marketing Network) -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenn... Biopharmaceuticals, Regulatory PTC Therapeutics, Translarna, ataluren, Duchenne muscular dystrophy (Source: HSMN NewsFeed)
2020-12-11
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) A muscle fiber consists of just one cell, but many nuclei. A team at the MDC led by Professor Carmen Birchmeier has now shown just how varied these nuclei are. The study, which has been published in Nature Communications, can help us better understand muscle diseases such as Duchenne muscular dystrophy. (Source: EurekAlert! - Medicine and Health)
2020-12-14
Basel, 14 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for OCREVUS ® (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). The approval was based on data from the randomised, double-blind ENSEMBLE PLUS study.“More than 170,000 people with MS have been treated with OCREVUS - the only approved B-cell therapy with a twice-yearly dosing schedule - and it is the most prescribed MS medicine in the U.S.,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Developmen t. “We constantly strive to improve the exp...<div id="medworm"><p><b><i>MedWorm Message:</i></b> If you are looking to buy something in the <a href="http://thejanuarysales.com/">January Sales</a> please visit <a href="http://thejanuarysales.com/">TheJanuarySales.com</a> for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.</p></div>
2021-01-01
Five years ago, Jay Schneider, M.D., Ph.D., was running a lab at The University of Texas Southwestern Medical Center in Dallas. The lab focused on researching cures for the genetic muscular-wasting disorder, Duchenne muscular dystrophy. His wife, Alice Chang, M.D., had accepted an offer to work at Mayo Clinic in Rochester, Minnesota, two years before. The [...] (Source: News from Mayo Clinic)
2020-12-21
(UT Southwestern Medical Center) A UT Southwestern research team has catalogued gene activity in the skeletal muscle of mice, comparing healthy animals to those carrying a genetic mutation that causes Duchene muscular dystrophy (DMD) in humans. The findings, published online recently in PNAS, could lead to new treatments for this devastating degenerative disease and insights into factors that affect muscle development. (Source: EurekAlert! - Medicine and Health)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Have you tried our new <a href="https://medworm.com/">medical search engine</a>? More powerful than before. Log on with your social media account. 100% free.</p></div>
2021-01-12
(Cedars-Sinai Medical Center) Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows. The findings, published in the peer-reviewed Journal of Extracellular Vesicles, could help develop new oral medications for treating patients with muscular dystrophy and heart failure. (Source: EurekAlert! - Medicine and Health)
2021-01-28
THURSDAY, Jan. 28, 2021 -- An experimental gene therapy for Duchenne muscular dystrophy shows promise, a small study suggests.
The severe form of muscular dystrophy -- which affects about one in 3,500 males born each year in the United States --... (Source: Drugs.com - Daily MedNews)
The severe form of muscular dystrophy -- which affects about one in 3,500 males born each year in the United States --... (Source: Drugs.com - Daily MedNews)
2021-01-28
Title: What Is the Best Treatment for Muscular Dystrophy?Category: Diseases and ConditionsCreated: 1/28/2021 12:00:00 AMLast Editorial Review: 1/28/2021 12:00:00 AM (Source: MedicineNet Kids Health General)
2020-12-14
Basel, 14 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for OCREVUS ® (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). The approval was based on data from the randomised, double-blind ENSEMBLE PLUS study.“More than 170,000 people with MS have been treated with OCREVUS - the only approved B-cell therapy with a twice-yearly dosing schedule - and it is the most prescribed MS medicine in the U.S.,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Developmen t. “We constantly strive to improve the exp...
2021-02-10
For me, and many others with physical disabilities, touch is not merely a luxury or a pleasure, but an aspect of my functionality, my basic survival. (Source: NYT Health)<div id="medworm"><p><b><i>MedWorm Message:</i></b> If you are looking to buy something in the <a href="http://thejanuarysales.com/">January Sales</a> please visit <a href="http://thejanuarysales.com/">TheJanuarySales.com</a> for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.</p></div>